Autopsy report · NCT04049578

A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Balovaptan in Children With Autism Spectrum Disorder

Cause of deathFutility Automatic label, confidence 0.9, unverified. How labels are made.

“Recent analysis of Phase II balovaptan data in paediatric ASD did not support the continuation of this study. No new safety concerns were identified.”

The sponsor’s own words in the registry.

Life of this trial

Registered 4 months before it started.
Ran for about 5 months before it stopped.
2 participants enrolled.
Results were posted on the registry 5 months after it ended.

Vital statistics

Status: Terminated
Phase: Phase 1
Sponsor: Hoffmann-La Roche
Sponsor type: Industry
Conditions: Autism Spectrum Disorder
Interventions: Balovaptan
Participants: 2
Sites: 5
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.